Expert Interview
Discussing Eyenovia’s Mydcombi FDA approval as the First Ophthalmic Spray for Mydriasis
Ticker(s): EYENInstitution: Scott & Christie & Associates
- Director of Clinical Research for Scott & Christie & Associates Eye Research Institute.
- Performs over 2000 diagnostic procedures inducing mydriasis a year.
- Research focus on advanced future technology of eyecare through clinical trials with a focus on dry eye, glaucoma, blepharitis, presbyopia, myopia and allergies.
What is the significance of FDA approval for Mydcombi and Eyenovia's Optejet device platform?
Can you explain the market potential for an ophthalmic spray for mydriasis and how it compares to existing methods?
Added By: slingshot_insightsHow can Mydcombi leverage Eyenovia's proprietary Optejet device platform? What advantages does this platform offer?
What were the key findings and results from the clinical trials leading to FDA approval?
Added By: slingshot_insightsWhat are the potential risks and side effects associated with using Mydcombi?
How does Mydcombi address the current unmet needs in ophthalmic care?
Added By: slingshot_insightsCan you provide details about the target patient population for Mydcombi and its expected adoption rate?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
